Abstract:Cancer represents the leading public health problem throughout the world. Globally, about one out of six deaths is related to cancer, which is largely due to the metastatic lesions. However, there are no effective strategies for targeting cancer metastasis. Identification of the key druggable targets maintaining metastasis is crucial for cancer treatment. In our recent study (Cai et al. (2020), Mol Cell, doi: 10.1016/j.molcel.2020.09.018), we found that activity of AMPK was enriched in metastatic tumors compared to primary tumors. Depletion of AMPK rendered cancer cells more sensitive to metabolic and oxidative stress, leading to the impairment of breast cancer lung metastasis. Activation of AMPK rewired cancer metabolism towards TCA cycle, which protects disseminated cancer cells from both metabolic and oxidative stress-induced cell death, and facilitates cancer metastasis. Further, AMPK critically maintained the activity of pyruvate dehydrogenase complex (PDH), the rate limiting enzyme involved in TCA cycle, thus favoring the pyruvate metabolism towards TCA cycle rather than converting it to lactate. Mechanistically, AMPK was shown to co-localize with PDHA, the catalytic subunit of PDH, in the mitochondrial matrix and directly triggered the phosphorylation of PDHA on Ser295 and Ser314. Hyper-phosphorylation of Ser295 and Ser314 of PDHA promotes lung metastasis through elevating activity of PDH. Of note, PDHA Ser314 phosphorylation abrogated the interaction between PDHA and PDHKs leading to the dephosphorylation on previously reported S293 site, whose phosphorylation serves as a negative signal for PDH activation, while S295 phosphorylation serves as an intrinsic catalytic site required for pyruvate metabolism. Our study presented the first evidence for the pro-metastatic property of the AMPK-PDH axis and advance our current understanding of how PDH is activated under physiological and pathological conditions.

Role of the LKB1/AMPK pathway in tumor invasion and metastasis of cancer cells (Review)

How is the AKT/mTOR Pathway Involved in Cell Migration and Invasion?

Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function.

LKB1 and Cancer: the Dual Role of Metabolic Regulation.

Posttranslational regulation of liver kinase B1 in human cancer

LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors

NUAK Kinases: Brain–Ovary Axis

Progress in antitumor mechanisms of liver kinase B1 gene

Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α

AMPK Inhibits the Stimulatory Effects of TGF-β on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition.

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth

AMPK and Cancer.

Enhanced Expression of LKB1 in Breast Cancer Cells Attenuates Angiogenesis, Invasion, and Metastatic Potential

LKB 1 / AMPK / Mtor Signaling Pathway in Non-small-cell Lung Cancer

Lactate Accelerates Cancer Progression Through the ERK-GCN5 Lactylation-Phosphorylation Feedback Cascade

Targeting AMPK for cancer prevention and treatment.

Cytoplasmic Liver Kinase B1 Promotes the Growth of Human Lung Adenocarcinoma by Enhancing Autophagy.

Tumor Suppressor LKB1 Inhibits the Progression of Gallbladder Carcinoma and Predicts the Prognosis of Patients with This Malignancy

AMP-activated Protein Kinase α2 Protects against Liver Injury from Metastasized Tumors via Reduced Glucose Deprivation-induced Oxidative Stress

AMPK maintains TCA cycle through sequential phosphorylation of PDHA to promote tumor metastasis

Functional Characterization of AMP-activated Protein Kinase Signaling in Tumorigenesis